Post-marketing study to assess the risk of intussusception after immunization with GlaxoSmithKline (GSK) Biologicals’ oral live-attenuated human rotavirus vaccine in infants less than 1 year old in Latin America (212329) First published 06/08/2025 Last updated 10/03/2026 EU PAS number:EUPAS1000000701 Study Ongoing